| pubmed-article:11920511 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11920511 | lifeskim:mentions | umls-concept:C1522449 | lld:lifeskim |
| pubmed-article:11920511 | lifeskim:mentions | umls-concept:C0272256 | lld:lifeskim |
| pubmed-article:11920511 | lifeskim:mentions | umls-concept:C0546816 | lld:lifeskim |
| pubmed-article:11920511 | lifeskim:mentions | umls-concept:C0027015 | lld:lifeskim |
| pubmed-article:11920511 | lifeskim:mentions | umls-concept:C1514474 | lld:lifeskim |
| pubmed-article:11920511 | lifeskim:mentions | umls-concept:C0439234 | lld:lifeskim |
| pubmed-article:11920511 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:11920511 | pubmed:dateCreated | 2002-3-28 | lld:pubmed |
| pubmed-article:11920511 | pubmed:abstractText | Prognostic factors for solitary plasmacytoma of bone (SPB), whether measured before or after radiotherapy (RT), have not been established. The authors analyzed multiple factors for myeloma-free survival (MFS) and cause-specific survival (CSS) in SPB patients treated with RT alone. | lld:pubmed |
| pubmed-article:11920511 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11920511 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11920511 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11920511 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11920511 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:11920511 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11920511 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11920511 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11920511 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:11920511 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:11920511 | pubmed:author | pubmed-author:WilderRichard... | lld:pubmed |
| pubmed-article:11920511 | pubmed:author | pubmed-author:HaChul SCS | lld:pubmed |
| pubmed-article:11920511 | pubmed:author | pubmed-author:CoxJames DJD | lld:pubmed |
| pubmed-article:11920511 | pubmed:author | pubmed-author:WeberDonnaD | lld:pubmed |
| pubmed-article:11920511 | pubmed:author | pubmed-author:DelasalleKayK | lld:pubmed |
| pubmed-article:11920511 | pubmed:author | pubmed-author:AlexanianRaym... | lld:pubmed |
| pubmed-article:11920511 | pubmed:copyrightInfo | Copyright 2002 American Cancer Society. | lld:pubmed |
| pubmed-article:11920511 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11920511 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:11920511 | pubmed:volume | 94 | lld:pubmed |
| pubmed-article:11920511 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11920511 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11920511 | pubmed:pagination | 1532-7 | lld:pubmed |
| pubmed-article:11920511 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:11920511 | pubmed:meshHeading | pubmed-meshheading:11920511... | lld:pubmed |
| pubmed-article:11920511 | pubmed:meshHeading | pubmed-meshheading:11920511... | lld:pubmed |
| pubmed-article:11920511 | pubmed:meshHeading | pubmed-meshheading:11920511... | lld:pubmed |
| pubmed-article:11920511 | pubmed:meshHeading | pubmed-meshheading:11920511... | lld:pubmed |
| pubmed-article:11920511 | pubmed:meshHeading | pubmed-meshheading:11920511... | lld:pubmed |
| pubmed-article:11920511 | pubmed:meshHeading | pubmed-meshheading:11920511... | lld:pubmed |
| pubmed-article:11920511 | pubmed:meshHeading | pubmed-meshheading:11920511... | lld:pubmed |
| pubmed-article:11920511 | pubmed:meshHeading | pubmed-meshheading:11920511... | lld:pubmed |
| pubmed-article:11920511 | pubmed:meshHeading | pubmed-meshheading:11920511... | lld:pubmed |
| pubmed-article:11920511 | pubmed:meshHeading | pubmed-meshheading:11920511... | lld:pubmed |
| pubmed-article:11920511 | pubmed:meshHeading | pubmed-meshheading:11920511... | lld:pubmed |
| pubmed-article:11920511 | pubmed:meshHeading | pubmed-meshheading:11920511... | lld:pubmed |
| pubmed-article:11920511 | pubmed:meshHeading | pubmed-meshheading:11920511... | lld:pubmed |
| pubmed-article:11920511 | pubmed:meshHeading | pubmed-meshheading:11920511... | lld:pubmed |
| pubmed-article:11920511 | pubmed:meshHeading | pubmed-meshheading:11920511... | lld:pubmed |
| pubmed-article:11920511 | pubmed:meshHeading | pubmed-meshheading:11920511... | lld:pubmed |
| pubmed-article:11920511 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:11920511 | pubmed:articleTitle | Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. | lld:pubmed |
| pubmed-article:11920511 | pubmed:affiliation | Department of Radiation Oncology, M.D. Anderson Cancer Center, Houston, Texas, USA. rwilder@mdanderson.org | lld:pubmed |
| pubmed-article:11920511 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11920511 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11920511 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11920511 | lld:pubmed |
